Synthesis, in vivo and in silico evaluation of novel 2,3‐dihydroquinazolin‐4(1H)‐one derivatives as potential anticonvulsant agents

Abstract

In light of the pharmacophoric structural requirements for achieving anticonvulsant activity, a series of N‐(1‐methyl‐4‐oxo‐2‐un/substituted‐1,2‐dihydroquinazolin‐3[4H]‐yl)benzamide (4a‐g) and N‐(1‐methyl‐4‐oxo‐2‐un/substituted‐1,2‐dihydroquinazolin‐3[4H]‐yl)‐2‐phenylacetamide (4h‐n) derivatives were synthesized in two steps starting from the reaction of N‐methyl isatoic anhydride with the appropriate hydrazide and followed by condensation with the appropriate aldehyde. The anticonvulsant activities of the synthesized compounds were evaluated according to the anticonvulsant drug development (ADD) programme protocol. Among the synthesized compounds, 4n showed promising activity in both the maximal electroshock (MES) and pentylenetetrazole (PTZ) tests with median effective dose (ED50) values of 40.7 and 6 mg/kg, respectively. The six most promising derivatives, 4b, 4a, 4c, 4f, 4j, and 4i, showed very low ED50 values in the PTZ test (3.1, 4.96, 8.68, 9.89, 12, and 13.53 mg/kg, respectively). All the tested compounds showed no to low neurotoxicity in the rotarod test with a wide therapeutic index. Docking studies of compound 4n suggested that GABAA binding could be the mechanism of action of these derivatives. The in silico drug likeliness parameters indicated that none of the designed compounds violate Lipinski's rule of five and that they are able to cross the blood–brain barrier. Hit, Lead & Candidate Discovery

Novel 5‐(1‐aryl‐1H‐pyrazol‐3‐yl)‐1H‐tetrazoles as glycogen phosphorylase inhibitors: An in vivo antihyperglycemic activity study

“…To be an effective antidiabetic drug, the candidate compounds must be able to cross the Blood Brain Barrier (BBB) to exert their action. They should also possess good pharmacokinetic and oral bioavailability properties (Kothayer, Ibrahim, Soltan, Rezq, & Mahmoud, ). The drug‐like properties of the designed compounds were predicted using the web tool Molinspiration (http://www.molinspiration.com) based on Lipinski's (2004) “Rule of five”.…”

“…They should also possess good pharmacokinetic and oral bioavailability properties (Kothayer, Ibrahim, Soltan, Rezq, & Mahmoud, 2018).…”

Salix tetrasperma Roxb. Extract Alleviates Neuropathic Pain in Rats via Modulation of the NF-κB/TNF-α/NOX/iNOS Pathway

“…The mice were put on a rotating rotarod that was set to accelerate from 0 to 40 rpm in 120 s and the time in seconds before the mouse falls was recorded in each trial (three total). A time of 300 s was set as the time limit of each trial [20].…”

Design and synthesis of novel quinazolinones conjugated ibuprofen, indole acetamide, or thioacetohydrazide as selective COX-2 inhibitors: anti-inflammatory, analgesic and anticancer activities

“…Further studies to explore the in vivo central anti-inflammatory potentials of both these compounds are currently in progress. This finding is especially relevant given that quinazolinone's ability to cross BBB as an anticonvulsant therapeutic is well reported 64,65 .…”